To Give or Not to Give Adjuvant Chemotherapy in Breast Cancer? Can CanAssist Breast Assist?

IF 0.6 Q4 ONCOLOGY
South Asian Journal of Cancer Pub Date : 2022-07-11 eCollection Date: 2022-01-01 DOI:10.1055/s-0042-1746411
Amol Akhade, Aju Mathew
{"title":"To Give or Not to Give Adjuvant Chemotherapy in Breast Cancer? Can CanAssist Breast Assist?","authors":"Amol Akhade, Aju Mathew","doi":"10.1055/s-0042-1746411","DOIUrl":null,"url":null,"abstract":"Survival of early-stage hormone receptor (HR)-positive and human epidermal receptor 2 (HER2)-negative breast cancer has signi fi cantly improved over the last three decades. Adjuvant chemotherapy plays an important role in this advance-ment. 1 However, we have also learnt that the bene fi t of chemotherapy is not for all patients. 2 Some patients may be overtreatedwithchemotherapyresultinginavoidabletoxicity. Some may be undertreated resulting in lackofcure. Therefore, a predictive biomarker is of great demand. Such a biomarker will helptheoncologist in deciding treatmentcourse, whether to give or not to give adjuvant chemotherapy. fi eld fi nessed","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"11 1","pages":"1-2"},"PeriodicalIF":0.6000,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/f1/10-1055-s-0042-1746411.PMC9273325.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Asian Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1746411","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Survival of early-stage hormone receptor (HR)-positive and human epidermal receptor 2 (HER2)-negative breast cancer has signi fi cantly improved over the last three decades. Adjuvant chemotherapy plays an important role in this advance-ment. 1 However, we have also learnt that the bene fi t of chemotherapy is not for all patients. 2 Some patients may be overtreatedwithchemotherapyresultinginavoidabletoxicity. Some may be undertreated resulting in lackofcure. Therefore, a predictive biomarker is of great demand. Such a biomarker will helptheoncologist in deciding treatmentcourse, whether to give or not to give adjuvant chemotherapy. fi eld fi nessed
乳腺癌患者是否应接受辅助化疗?CanAssist可以帮助乳房吗?
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
80
审稿时长
35 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信